Aldeyra Therapeutics stock plunges 70% after third FDA rejection

Aldeyra Therapeutics shares fell 70% after the FDA issued a third rejection for its dry-eye drug, citing a lack of evidence ...
MPR

FDA Issues Third CRL for Reproxalap in Dry Eye Disease

Previously, the Company had received CRLs in November 2023 and April 2025 due to insufficient evidence in addressing the ...

FDA rejects Aldeyra's dry eye drug for third time, stock crashes 68%

Aldeyra Therapeutics Inc. ALDX shares are tumbling on Tuesday following the U.S. Food and Drug Administration (FDA) update.
Fierce Biotech

FDA rejects Aldeyra dry eye disease drug for 3rd time, citing inconsistent study findings

After delaying its review, the FDA has rejected Aldeyra Therapeutics’ experimental dry eye disease treatment for the third ...
BioSpace

Third FDA Rejection for Aldeyra’s Dry Eye Disease Drug Sends Shares Plummeting

In its complete response letter, the FDA said Aldeyra had failed to demonstrate reproxalap’s efficacy in adequate and ...
InvestorsHub on MSN

Aldeyra receives FDA rejection for dry eye treatment reproxalap

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) said it has received a Complete Response Letter from the U.S. Food and Drug ...
Ophthalmology Times

Aldeyra receives third complete response letter for reproxalap

The US Food and Drug Administration (FDA) has issued a Complete Response Letter to Aldeyra Therapeutics for its New Drug Application of reproxalap for the treatment of dry eye dis ...

Aldeyra Therapeutics Shares Fall as Drug Rejected by Regulator on Efficacy Concerns

Shares of Aldeyra Therapeutics fell sharply in premarket trading Tuesday said the U.S. health regulator rejected its dry-eye drug, saying that the company failed to show the treatment works. Shares ...

‘Dry to the bone’: Drought squeezes Everglades airboat operators

Instead of whizzing through the open marsh of the Everglades like he usually does, Tristan Tigertail steers his airboat ...
Optometry Advisor

Symptom-Sign Discordance Prevalent in Moderate-to-Severe Dry Eye Disease

Study reveals that 77% of patients with moderate-to-severe dry eye disease exhibit discordance between clinical signs and ...

Nanodropper Launches the First-Ever "Eye Drop Score" to Help Patients Improve Their Eye Drop Routine

ROCHESTER, Minn., March 13, 2026 /PRNewswire/ -- Nanodropper Inc. today announced the launch of the Eye Drop Score, a first-of-its-kind self-check quiz designed to help people who rely on prescription ...
Medscape

Light Therapy May Improve Vision in Patients With Dry AMD

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related ...